查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1988071

金諾芬市場：2026-2032年全球市場預測（依適應症、治療領域、劑型、最終用戶和通路分類）

Auranofin Market by Indication, Therapeutic Class, Dosage Strength, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，金諾芬市值將達到 2.3002 億美元，到 2026 年將成長至 2.4773 億美元，到 2032 年將達到 3.2296 億美元，複合年成長率為 4.96%。

主要市場統計數據
基準年 2025 2.3002億美元
預計年份：2026年 2.4773億美元
預測年份 2032 3.2296億美元
複合年成長率 (%) 4.96%

金諾芬在腫瘤學和類風濕性關節炎領域的重新定位表明，跨學科合作為改善治療研發和療效提供了機會。

金諾芬（Auranofin）作為一種具有悠久治療歷史的藥物，因其不斷擴展的臨床訊號通路和對藥理學認知的加深而重新受到關注。金諾芬最初是為治療風濕性疾病而研發和應用的，如今其作用機制因其潛在的抗癌和免疫調節作用而備受矚目。這種重新評估促使包括臨床研究人員、藥物遴選委員會、製藥公司和保險公司在內的眾多相關人員重新審視金諾芬在現代治療體系中的地位。

科學進步、監管變化和商業化趨勢共同作用，重新定義了奧拉諾芬的臨床定位和臨床實驗設計重點。

目前，金諾芬在科學、監管和商業性實施等多個領域正經歷著變革性的變化。在科學方面，我們對氧化還原生物學、蛋白質穩態和免疫調節的理解不斷深入，揭示了金諾芬可能發揮超出其預期適應症的有益作用的潛在機制。這些新發現，結合更先進的生物標記和轉化模型，正在塑造現代臨床項目和假設主導臨床試驗的設計。

預計美國將在 2025 年調整關稅，這對金諾芬供應鏈的韌性、採購成本和臨床試驗營運產生影響。

2025年美國關稅政策的變化將對包括奧拉諾芬在內的藥品供應鏈產生影響。如果活性成分、包裝材料或輔助材料來自海外，這種影響將特別顯著。關稅調整可能會改變製造商和合約夥伴的採購成本結構，促使他們重新評估供應商、修訂合約並調整庫存策略。這些因應措施通常與增強供應鏈韌性、降低單一來源依賴風險的努力同時進行。

對影響奧拉諾芬臨床應用和市場定位的因素進行關鍵細分分析，按適應症、治療領域、通路和劑量進行細分。

細分市場層面的趨勢提供了關於如何在臨床和營運環境中評估和實施奧拉諾芬的重要背景資訊。從適應症來看，重點產品組合集中在腫瘤和類風濕性關節炎。在腫瘤領域，重點是白血病和淋巴瘤患者群體，基於作用機制的證據和初步數據，這些患者群體可能從中獲益。同時，在類風濕性關節炎領域，重點在於區分中度和重度疾病狀態，以便調整對安全性監測和比較證據的預期。

美洲、歐洲、中東和非洲以及亞太地區的區域洞察：重點關注奧拉諾芬臨床導入、監管細微差別和市場准入趨勢的差異

區域差異影響著奧拉諾芬的臨床應用、監管預期和供應策略。在美洲，臨床開發往往由廣泛的研究者主導的計畫和緊密的學術機構網路推動，這使得假設能夠快速檢驗，同時也要求與支付方的證據要求和醫院採購的實際考慮高度契合。

從公司層面深入了解奧拉諾芬的研發重點、授權和合作活動、製造和供應方法以及差異化策略。

企業行動和策略定位對於奧拉諾芬計畫從概念階段到臨床試驗再到最終廣泛應用的整個過程至關重要。不同機構的研發重點各不相同；有些機構優先考慮闡明藥物作用機制和早期臨床試驗，而有些機構則專注於後期對比試驗，以滿足臨床醫生和支付方的循證需求。許可和合作通常被用作加速研發、擴大生產和分銷能力的手段，而無需完全自主建構基礎設施。

加強奧拉諾芬研發路徑、保障供應鏈、改善試驗設計、改善臨床應用等的實用建議。

產業領導者應採取切實可行的優先措施，使科學預期與營運和市場准入的實際情況相符。首先，證據策略的製定應目標明確。申辦者應儘早明確臨床醫師和支付者最關注的臨床終點和真實世界終點，並設計能夠產生與這些相關人員相關的比較數據和轉化數據的臨床試驗。這有助於減少後續環節的阻力，並在結果積極的情況下促進快速應用於臨床實踐。

調查方法，結合有針對性的初步訪談、結構化的二次研究和嚴格的檢驗，以檢驗跨細分市場和地區的見解。

本研究途徑整合了多方面的證據來源和檢驗步驟，以確保分析的嚴謹性和有效性。主要研究包括對臨床醫生、供應鏈專家、監管顧問和臨床實驗管理人員進行有針對性的保密訪談，以收集關於臨床假設、營運限制和證據需求的第一手觀點。這些訪談旨在識別不同適應症、治療領域和最終使用環境中的實際障礙和潛在的緩解策略。

我們將負責任地推廣奧拉諾芬，並將臨床進展、政策和供應風險、細分市場機會以及相關人員的行為納入我們的結論中。

現有證據表明，金諾芬有望成為重新定位的候選藥物，其作用日益凸顯，這需要臨床、監管和營運等多個領域的協調努力。在臨床方面，金諾芬在腫瘤和類風濕性關節炎領域的應用凸顯了其廣泛的潛在適用性，以及製定針對特定適應症的證據策略的必要性。在營運方面，分銷管道和終端用戶環境的差異表明，製劑、包裝和支援服務對藥物的實際應用效果有顯著影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：奧拉諾芬市場：依適應症分類

  • 腫瘤學
    • 白血病
    • 淋巴瘤
  • 類風濕性關節炎
    • 緩和
    • 嚴重

第9章：依治療分類分類的奧拉諾芬市場

  • DMARD
    • 生物製藥
    • 傳統的
    • 標靶定向藥物
  • 黃金製劑

第10章：以劑量強度分類的奧拉諾芬市場

  • 3mg
  • 6mg

第11章 金諾芬市場：以最終用戶分類

  • 居家照護設施
  • 醫院
  • 專科診所

第12章 金諾芬市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 金諾芬市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 金諾芬市場：依集團分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 金諾芬市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國奧拉諾芬市場

第17章：中國奧拉諾芬市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AGC Inc.
  • Ardagh Group SA
  • Corning Incorporated
  • Guardian Industries
  • Nippon Electric Glass Co. Ltd.
  • Owens-Illinois Inc.
  • Pilkington Group Limited
  • PPG Industries Inc.
  • Saint-Gobain SA
  • Schott AG
  • Vitro SAB de CV
Product Code: MRR-F97DD5A7D98B

The Auranofin Market was valued at USD 230.02 million in 2025 and is projected to grow to USD 247.73 million in 2026, with a CAGR of 4.96%, reaching USD 322.96 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 230.02 million
Estimated Year [2026] USD 247.73 million
Forecast Year [2032] USD 322.96 million
CAGR (%) 4.96%

Auranofin repositioning across oncology and rheumatoid arthritis signaling cross-disciplinary opportunities to enhance therapeutic development and outcomes

Auranofin has emerged from a longstanding therapeutic history with renewed interest driven by expanding clinical signals and a clearer understanding of its pharmacology. Initially developed and deployed in the context of rheumatologic indications, its mechanisms of action have attracted attention for potential anticancer and immunomodulatory uses. This repositioning has prompted a wide array of stakeholders-clinical investigators, formulary committees, manufacturers, and payers-to reassess where auranofin fits within contemporary treatment frameworks.

As clinical programs evolve, the drug's profile is being examined in parallel pathways: continued relevance in immune-mediated disease and growing exploration within oncology. This dual trajectory has introduced novel considerations around dosing strategies, safety monitoring, and comparative positioning relative to alternative therapeutic classes. At the same time, changes in regulatory expectations and payer scrutiny are influencing development strategies and evidence generation plans.

Taken together, these dynamics create both opportunity and complexity. Organizations engaging with auranofin must balance the demand for robust clinical validation with practical imperatives such as reliable supply, appropriate distribution arrangements, and clear value communication for clinicians and patients. The introduction establishes why auranofin's renewed relevance warrants careful strategic planning across clinical, operational, and access-related domains.

Scientific advances, regulatory shifts, and commercialization trends converging to redefine auranofin's clinical positioning and trial design priorities

The landscape for auranofin is undergoing several transformative shifts that span science, regulation, and commercial execution. On the scientific front, advances in understanding redox biology, protein homeostasis, and immune modulation have clarified plausible mechanisms through which auranofin could exert benefit beyond its original indication. These mechanistic insights have coincided with more sophisticated biomarkers and translational models, which together are shaping the design of contemporary clinical programs and hypothesis-driven trials.

Regulatory pathways have also recalibrated in ways that matter for repositioned drugs. Agencies increasingly encourage adaptive trial designs and real-world evidence integration when safety profiles are well-characterized, creating both pathways and expectations for sponsors. At the same time, heightened attention to benefit-risk balance and cost-effectiveness means that evidentiary strategies must be tightly aligned to payer and clinician needs from an earlier stage.

Commercially, shifts in distribution logistics, sourcing strategies, and manufacturer partnerships are influencing how developers think about scale-up and access. Strategic alliances-ranging from licensing agreements to contract manufacturing relationships-provide routes to secure supply, while collaborative research models enable more rapid validation of new indications. Together, these scientific, regulatory, and commercial inflections are redefining how stakeholders prioritize investments and allocate resources in support of auranofin's next-generation programs.

Anticipated United States tariff adjustments in 2025 and their effects on auranofin supply chain resilience, procurement costs, and clinical trial operations

Changes to tariff policy in the United States in 2025 have implications for pharmaceutical supply chains that extend to drugs like auranofin, particularly where active pharmaceutical ingredients, packaging, or secondary components are sourced internationally. Tariff adjustments can alter procurement economics for manufacturers and contract partners, prompting reassessments of sourcing locations, supplier contracts, and inventory strategies. These operational responses often happen alongside efforts to shore up resilience and reduce exposure to single-source dependencies.

Clinical research operations are also affected by shifts in import/export costs. Increased tariffs on raw materials or finished goods can influence trial budgets and logistics, especially for multicenter studies that rely on centralized supply distribution. Sponsors may need to modify shipment schedules, identify alternative vendors, or engage additional contingency planning to preserve trial timelines and data integrity. Importantly, procurement tactics that emphasize diversification and nearshoring can mitigate volatility but require lead time to implement.

Finally, payers and providers may experience downstream effects, as procurement cost pressures can influence formulary decisions and hospital purchasing agreements. Organizations considering expanded development or wider deployment of auranofin should therefore integrate tariff-related scenarios into supply planning, contract negotiations, and clinical operations so that contingency measures are in place to maintain continuity of care and research momentum.

Key segmentation insights revealing drivers of clinical application and positioning for auranofin across indications, therapy classes, channels, and dosages

Segment-level dynamics provide essential context for how auranofin is being evaluated and deployed in clinical and operational settings. When viewed by indication, the portfolio of interest clusters into oncology and rheumatoid arthritis; within oncology, focused efforts concentrate on leukemia and lymphoma populations where mechanistic rationale and preliminary data suggest potential benefit, while within rheumatoid arthritis attention differentiates between moderate and severe disease states to tailor safety monitoring and comparative evidence expectations.

Therapeutic class segmentation further clarifies positioning. Auranofin sits in the broader class of disease-modifying antirheumatic drugs and in the niche of gold compounds, prompting comparisons to biologics, conventional DMARDs, and targeted synthetic agents. These comparisons influence clinical trial endpoints and the kinds of head-to-head data that stakeholders often request, as well as the profile of real-world evidence that will support adoption in practice.

Distribution channel distinctions matter operationally and for patient access. Hospital pharmacies, online pharmacies, and retail pharmacies each have different procurement cycles, inventory management practices, and patient touchpoints, which in turn shape fulfillment strategies and clinician prescribing behavior. End-user segmentation-distinguishing home care settings from hospitals and specialty clinics-also drives packaging, dosing convenience, and support services that may be necessary for safe and effective use. Finally, dosage strength segmentation, typically between 3mg and 6mg formulations, underpins dosing algorithms, therapeutic monitoring plans, and comparative tolerability discussions. Integrating these layered segments enables stakeholders to make nuanced decisions about clinical evidence generation, supply arrangements, and adoption strategies that reflect real-world care pathways.

Regional insights across Americas, EMEA, and Asia-Pacific that highlight differences in clinical adoption, regulatory nuance, and access dynamics for auranofin

Regional variations shape clinical adoption, regulatory expectations, and supply strategies for auranofin. In the Americas, clinical development tends to be driven by extensive investigator-led programs and a dense network of academic centers, which supports rapid hypothesis testing but also requires strong alignment with payer evidence requirements and practical considerations for hospital procurement.

In Europe, Middle East & Africa, regulatory frameworks and reimbursement pathways vary markedly by country and region, creating a mosaic of evidence needs and access timelines. Stakeholders operating in this broader region must navigate heterogeneous HTA processes, diverse pricing dynamics, and distinct clinical practice patterns that influence how new or repurposed therapies are adopted.

Asia-Pacific exhibits its own set of drivers: rapid expansion of clinical trial capacity in several countries, strong manufacturing capabilities, and varied reimbursement environments. These factors create opportunities for regional manufacturing partnerships, accelerated enrollment for appropriately designed trials, and a need to calibrate evidence packages so they meet multiple regulatory and clinical expectations. Across all regions, local supply chain arrangements, distribution partners, and clinician education initiatives are critical to translating clinical evidence into practical availability for patients.

Company-level insights on R&D focus, licensing and partnership activity, manufacturing and supply approaches, and differentiation strategies around auranofin

Company behavior and strategic positioning are central to how auranofin programs progress from concept to clinic and to broader availability. Research and development focus varies across organizations, with some prioritizing mechanistic exploration and early-phase trials while others emphasize late-stage comparative studies that address clinician and payer evidence needs. Licensing and partnership activity frequently emerge as mechanisms to accelerate development or to expand manufacturing and distribution capabilities without the need for fully internalized infrastructure.

Manufacturing and supply strategies are another area of differentiation. Some companies invest in vertical integration to secure key active pharmaceutical ingredient flows, while others rely on contract manufacturing organizations and distributed supplier networks that can be reconfigured as demand evolves. Decisions about formulation, packaging, and dosage strengths influence not just clinical protocols but also production batch sizes, inventory strategies, and distribution suitability for hospital, retail, or home care settings.

Competitive differentiation often centers on the quality and specificity of the evidence base, the robustness of supply commitments, and the effectiveness of stakeholder engagement. Organizations that proactively align clinical programs with real-world needs, secure resilient supply arrangements, and cultivate collaborative relationships with clinical networks tend to preserve optionality and reduce implementation friction. These corporate-level choices define the trajectory of auranofin from investigational programs to practical therapeutic options.

Actionable recommendations to strengthen development pathways, secure supply chains, refine trial design, and improve clinical access for auranofin

Industry leaders should adopt pragmatic, prioritized actions to align scientific promise with operational and access realities. First, evidence strategies should be purpose-built: sponsors ought to define the clinical and real-world endpoints that matter most to clinicians and payers early, and design trials that generate comparative and translational data suited to those stakeholders. This reduces downstream friction and supports more rapid assimilation into clinical practice when results are positive.

Second, supply chain robustness must be elevated to a strategic priority. Organizations should map critical suppliers, assess single-source vulnerabilities, and develop alternative sourcing or nearshoring plans where appropriate. These steps enable continuity for both clinical programs and patient supply while tariffs and trade dynamics evolve.

Third, distribution and end-user needs must inform product and service design. Packaging, dosing regimens, and patient support services should be tailored to hospitals, specialty clinics, and home care settings to optimize adherence and safety. Finally, stakeholders should pursue collaborative approaches-whether through licensing, strategic partnerships, or investigator consortia-to share risk, access specialized capabilities, and accelerate evidence generation. Prioritizing these actions will improve the likelihood of responsible, scalable adoption and minimize operational disruptions.

Methodology combining targeted primary interviews, structured secondary research, and rigorous triangulation to validate insights across segments and regions

The research approach integrates multiple evidence streams and validation steps to ensure analytic rigor and relevance. Primary research included targeted, confidential interviews with clinicians, supply chain specialists, regulatory advisors, and trial operations leads to capture first-hand perspectives on clinical hypotheses, operational constraints, and evidence needs. These interviews were structured to surface practical barriers and potential mitigations across indications, therapeutic classes, and end-use settings.

Secondary research comprised a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to synthesize mechanistic understanding, safety data, and programmatic trends. Findings from primary and secondary sources were then subjected to triangulation: convergent themes were identified, divergent viewpoints were traced back to context, and key assertions were tested against multiple independent information points.

Throughout the process, attention was given to segment and regional specificity so that conclusions reflect the differences between clinical indications, therapeutic classes, distribution pathways, end users, and dosage strengths, as well as geographic distinctions. This layered methodology supports actionable insights that stakeholders can apply to clinical planning, supply decisions, and strategic partnerships.

Integrated conclusion synthesizing clinical momentum, policy and supply risks, segmentation opportunities, and stakeholder actions to responsibly advance auranofin

The evidence gathered points to auranofin's evolving role as a candidate for repositioning that demands coordinated attention across clinical, regulatory, and operational domains. Clinically, the dual focus on oncology and rheumatoid arthritis highlights both the breadth of potential applications and the need for indication-specific evidence strategies. Operationally, distribution channel distinctions and end-user settings underscore that formulation, packaging, and support services materially affect real-world usability.

Policy and supply considerations are equally consequential. Tariff dynamics, procurement practices, and manufacturing footprints will influence the feasibility of broad deployment and trial continuity. Responding to these factors requires proactive supply planning, flexible sourcing, and contractual safeguards that preserve access during periods of trade or logistic volatility.

Taken together, the most effective responses will be multidisciplinary: sponsors and manufacturers must coordinate trial design with operational logistics and payer engagement, while health systems should prepare clinical pathways that reflect differences in dosing, administration settings, and evidence thresholds. By centering strategy on validated clinical priorities, resilient supply arrangements, and clear stakeholder communication, organizations can responsibly advance auranofin programs and translate scientific potential into meaningful patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Auranofin Market, by Indication

  • 8.1. Oncology
    • 8.1.1. Leukemia
    • 8.1.2. Lymphoma
  • 8.2. Rheumatoid Arthritis
    • 8.2.1. Moderate
    • 8.2.2. Severe

9. Auranofin Market, by Therapeutic Class

  • 9.1. DMARDS
    • 9.1.1. Biologics
    • 9.1.2. Conventional
    • 9.1.3. Targeted Synthetic
  • 9.2. Gold Compounds

10. Auranofin Market, by Dosage Strength

  • 10.1. 3mg
  • 10.2. 6mg

11. Auranofin Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Auranofin Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Auranofin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Auranofin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Auranofin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Auranofin Market

17. China Auranofin Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AGC Inc.
  • 18.6. Ardagh Group S.A.
  • 18.7. Corning Incorporated
  • 18.8. Guardian Industries
  • 18.9. Nippon Electric Glass Co. Ltd.
  • 18.10. Owens-Illinois Inc.
  • 18.11. Pilkington Group Limited
  • 18.12. PPG Industries Inc.
  • 18.13. Saint-Gobain S.A.
  • 18.14. Schott AG
  • 18.15. Vitro S.A.B. de C.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AURANOFIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL AURANOFIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 157. GCC AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. G7 AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 184. G7 AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. NATO AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 193. NATO AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA AURANOFIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA AURANOFIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)